Halozyme Therapeutics, Inc. (HALO) announced that it has withdrawn its non-binding proposal to acquire Evotec SE (EVO) for €11.00 per share in cash. The acquisition offer implied a fully diluted equity value of €2.0 billion.Halozyme decided to withdraw the acquisition bid following the unwillingness of Evotec’s management to discuss the potential buyout offer. EVO maintained its desire to remain an independent company.Besides withdrawing the buyout offer, HALO also reaffirmed its 2024 revenue guidance that ...